#pharmapartnership #diabetescare #obesitytreatment #glp1therapy...

ha condiviso un link

2025-10-24 09:57:54 -

Eli Lilly and Cipla have partnered to expand access to Tirzepatide (Yurpeak®) in India, marking a strategic move to address the country’s growing diabetes and obesity burden. Under this agreement, Lilly will handle manufacturing while Cipla leverages its extensive distribution network to enhance patient reach, especially in tier-2 and tier-3 cities.

Get More Insights on the topic -https://www.linkedin.com/feed/update/urn:li:activity:7387392185983238145/

Eli Lilly and Cipla have partnered to expand access to Tirzepatide (Yurpeak®) in India, marking a strategic move to address the country’s growing diabetes and obesity burden. Under this agreement, Lilly will handle manufacturing while Cipla leverages its extensive distribution network to enhance patient reach, especially in tier-2 and tier-3 cities. Get More Insights on the topic -https://www.linkedin.com/feed/update/urn:li:activity:7387392185983238145/

WWW.LINKEDIN.COM

#pharmapartnership #diabetescare #obesitytreatment #glp1therapy #yurpeak #mounjaro #healthcareinnovation #indiahealthcare #patientaccess #pharmamarketing #healthforall #pharmastrategy… | SPER Market Research®

𝐋𝐢𝐥𝐥𝐲 𝐚𝐧𝐝 𝐂𝐢𝐩𝐥𝐚 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐭𝐨 𝐄𝐱𝐩𝐚𝐧𝐝 𝐀𝐜𝐜𝐞𝐬𝐬 𝐭𝐨 𝐓𝐢𝐫𝐳𝐞𝐩𝐚𝐭𝐢𝐝𝐞 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚 Eli Lilly and Company has entered a strategic agreement with Cipla Limited, granting Cipla exclusive rights to distribute and promote Lilly's GLP-1 receptor agonist, tirzepatide, in India under the new brand 𝐘𝐮𝐫𝐩𝐞𝐚𝐤®. This follows Eli Lilly and Company’s own 𝐌𝐨𝐮𝐧𝐣𝐚𝐫𝐨®, already available for type 2 diabetes and chronic weight management. #PharmaPartnership #DiabetesCare #ObesityTreatment #GLP1Therapy #Yurpeak #Mounjaro #HealthcareInnovation 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬: ▪️ 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 & 𝐒𝐮𝐩𝐩𝐥𝐲: Lilly continues to handle production. ▪️ 𝐂𝐢𝐩𝐥𝐚’𝐬 𝐑𝐨𝐥𝐞: Leverages its pan-India distribution and promotional reach to expand patient access. ▪️ 𝐎𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐞: Address growing demand for diabetes and obesity therapies in India, where over 100 million people live with diabetes. #IndiaHealthcare #PatientAccess #PharmaMarketing #HealthForAll 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐦𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬: ▪️ 𝐅𝐚𝐬𝐭𝐞𝐫 𝐀𝐜𝐜𝐞𝐬𝐬 & 𝐏𝐞𝐧𝐞𝐭𝐫𝐚𝐭𝐢𝐨𝐧: Cipla’s extensive network could accelerate Yurpeak’s rollout, particularly in tier-2/3 cities and rural areas, potentially doubling tirzepatide’s market share in 12–18 months. ▪️ 𝐏𝐫𝐢𝐜𝐢𝐧𝐠 & 𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐨𝐧: Dual branding may introduce competitive pricing, putting pressure on rivals and enhancing affordability. ▪️ 𝐄𝐯𝐨𝐥𝐯𝐢𝐧𝐠 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐌𝐨𝐝𝐞𝐥𝐬: Reflects a growing trend of global pharma partnering with local companies to navigate India’s regulatory landscape, reducing market risk for innovators while boosting local specialty portfolios. #PharmaStrategy #EmergingMarkets #AffordableHealthcare #HealthEquity #DigitalHealthIndia ▪️ 𝐑𝐞𝐯𝐞𝐧𝐮𝐞 & 𝐒𝐭𝐨𝐜𝐤 𝐄𝐟𝐟𝐞𝐜𝐭𝐬: Cipla could see a revenue boost in FY26, while Lilly may increase India sales, though brand positioning will need careful management. This partnership is already generating positive buzz, with Cipla's shares initially rising ~2% on the news before some profit-taking on October 24. #HealthcareStocks #PharmaNews #InvestorInsights #Cipla #LillyIndia ▪️ 𝐁𝐫𝐨𝐚𝐝𝐞𝐫 𝐄𝐜𝐨𝐬𝐲𝐬𝐭𝐞𝐦 𝐈𝐦𝐩𝐚𝐜𝐭: Greater tirzepatide availability may drive clinical adoption, reduce comorbidity burdens, and influence R&D priorities for next-generation GLP-1 therapies. #MedicalInnovation #ClinicalAdoption #RDTherapies #FutureOfMedicine This collaboration underscores Lilly’s commitment to emerging markets and positions Cipla as a key partner in bringing innovative therapies to Indian patients, reflecting a more collaborative yet competitive pharma landscape. #GlobalHealth #PharmaLeadership #HealthcareCollaboration #InnovationInHealthcare #SPERMarketResearch

0 Commenti 0 condivisioni